[go: up one dir, main page]

KR20180081938A - 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물 - Google Patents

니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물 Download PDF

Info

Publication number
KR20180081938A
KR20180081938A KR1020170002870A KR20170002870A KR20180081938A KR 20180081938 A KR20180081938 A KR 20180081938A KR 1020170002870 A KR1020170002870 A KR 1020170002870A KR 20170002870 A KR20170002870 A KR 20170002870A KR 20180081938 A KR20180081938 A KR 20180081938A
Authority
KR
South Korea
Prior art keywords
ras
cancer
pharmaceutical composition
activity
gsk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020170002870A
Other languages
English (en)
Korean (ko)
Inventor
육종인
김현실
김남희
노경태
최지원
안성용
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to KR1020170002870A priority Critical patent/KR20180081938A/ko
Priority to PCT/KR2018/000396 priority patent/WO2018128517A1/fr
Publication of KR20180081938A publication Critical patent/KR20180081938A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020170002870A 2017-01-09 2017-01-09 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물 Ceased KR20180081938A (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020170002870A KR20180081938A (ko) 2017-01-09 2017-01-09 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물
PCT/KR2018/000396 WO2018128517A1 (fr) 2017-01-09 2018-01-09 Composition pharmaceutique contenant du niclosamide pour le traitement ou la prévention du cancer dans le cadre d'un traitement ciblant l'oncogène ras

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170002870A KR20180081938A (ko) 2017-01-09 2017-01-09 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물

Publications (1)

Publication Number Publication Date
KR20180081938A true KR20180081938A (ko) 2018-07-18

Family

ID=62791043

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170002870A Ceased KR20180081938A (ko) 2017-01-09 2017-01-09 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물

Country Status (2)

Country Link
KR (1) KR20180081938A (fr)
WO (1) WO2018128517A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
ES2647072T3 (es) * 2011-04-18 2017-12-19 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Niclosamida para el tratamiento de la metástasis en el cáncer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
비특허문헌 1 (연세대학교 대학원 박사학위논문, 2016) *
비특허문헌 2 (Cancer Res., 2011) *

Also Published As

Publication number Publication date
WO2018128517A1 (fr) 2018-07-12

Similar Documents

Publication Publication Date Title
ES2685947T3 (es) Agentes antienvejecimiento
DE60202727T2 (de) Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie
US9597325B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
KR101928543B1 (ko) 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
Mozafari et al. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer
JP2003508443A (ja) ジテルペノイドトリエポキシドの抗増殖剤としての使用
US11596613B2 (en) Compositions and methods for treating cancer
Zhou et al. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo
WO2007059372A2 (fr) Utilisation de chloroquine en vue de traiter un syndrome metabolique
US20230035892A1 (en) Methods and compositions for treating cancer
Wang The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors
US8957107B2 (en) Method of treating scars and β-catenin-mediated disorders using Nefopam compounds
Fatima et al. Curcumin and its derivatives targeting multiple signaling pathways to elicit anticancer activity: A comprehensive perspective
US10392398B2 (en) Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics
Li et al. Topical application of a dual ABC transporter substrate and NF-κB inhibitor blocks multiple sources of cutaneous inflammation in mouse skin
WO2009108755A2 (fr) Compositions pharmaceutiques pour le traitement du cancer
US9802948B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
CN115813892B (zh) 原儿茶醛与达卡巴嗪的药物联合及其在治疗恶性黑色素瘤中的用途
US20100272710A1 (en) Compositions and methods for treating and preventing aging-associated diseases
KR20180081938A (ko) 니클로사미드를 함유하는 Ras 암유전자 표적치료 관련 암의 치료 또는 예방용 약학 조성물
AU2023360058A1 (en) Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones.
US20080261911A1 (en) Uses of diphenyl/diphenylamine carboxylic acids
US20070259829A1 (en) Uses of diphenyl/diphenylamine carboxylic acids
JP2007145745A (ja) 変異型ＥＧＦＲ下流シグナルを抑制するＳｒｃファミリーチロシンキナーゼ阻害剤を含む肺癌治療剤およびその利用
CA2392093A1 (fr) Utilisation des ains dans le traitement du cancer du pancreas

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20170109

PA0201 Request for examination
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171115

Patent event code: PE09021S01D

AMND Amendment
PG1501 Laying open of application
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180724

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171115

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180724

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180413

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20181004

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180919

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180724

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180413

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20171115